Background
==========

The Pathosystems Resource Integration Center (PATRIC) is one of four bioinformatics resource centers (BRCs) funded by the National Institute of Allergy and Infectious Diseases (NIAID) \[[@bbx083-B1]\]. The BRC program supports research by providing access to data associated with the NIAID Category A--C pathogenic genera \[[@bbx083-B2]\], with PATRIC serving as the bacterial database. To provide a rich comparative analysis environment, PATRIC provides access to all publicly available genomes and associated metadata for bacterial and archaeal isolates, which includes \>104 000 genomes as of June 2017.

All of the genomes in PATRIC have been consistently annotated using the Rapid Annotation using Subsystems Technology toolkit (RASTtk) \[[@bbx083-B3], [@bbx083-B4]\]. This annotation consistency and subsequent protein family generation \[[@bbx083-B5]\] serve as the backbone for many of the comparative analysis tools on the Web site \[[@bbx083-B1]\]. The PATRIC database retains the annotations and identifiers from both GenBank \[[@bbx083-B6], [@bbx083-B7]\] and RefSeq \[[@bbx083-B8]\] to facilitate side-by-side comparisons across the public data, allowing researchers to quickly find genomes and genes with information that they have gathered from different resources. PATRIC also provides researchers with a private workspace, where they can access bioinformatics services including genome assembly, annotation, RNA sequencing, variation calling, Tn-Seq, similar genome finder, proteome comparison and metabolic model reconstruction. When a user annotates a private genome with the PATRIC annotation service, they can compare their genome with the public collection. This 'virtual integration' provides a unique analysis experience that is not available at a similar scale at any other data repository.

Facilitating research on antimicrobial resistance (AMR) has become increasingly important with the recent escalation in resistance and the loss of effectiveness to first-line drugs \[[@bbx083-B9]\]. This resistance has a human cost, with ∼2 million people being sickened and 23 000 dying annually in the United States alone \[[@bbx083-B14]\]. Here, we describe a set of enhancements introduced to support research on AMR.

AMR strategy
============

The current strategy for integrating AMR data into PATRIC breaks down roughly into two parts: (1) data collection to support analyses of whole genomes and (2) data collection to support analyses of individual proteins ([Figure 1](#bbx083-F1){ref-type="fig"}). In both cases, the data are drawn from the literature as well as a number of public resources. Specifics on the data integration, curation and tools are described below.

![PATRIC annotation process for integrating AMR data in both genomic regions and genes.](bbx083f1){#bbx083-F1}

AMR---integrating data at the genome level
==========================================

Data collection
---------------

To support an environment for comparative analysis, we integrate metadata associated with the public genomes at GenBank \[[@bbx083-B7]\] into the PATRIC database. This makes it easy to build sets of genomes that are based on collection date, geographic location, host, isolation source, etc. These metadata fields are incorporated both from BioSample \[[@bbx083-B15]\] and directly from the GenBank file when an assembled genome is added to PATRIC. In some cases, metadata are acquired first hand from the NIAID-funded genome sequencing centers and from collaborators wishing to make their data public. Given the increasing emphasis on research to combat AMR and the decreasing costs of sequencing, we have been able to collect a large number of genomes with AMR panel data in the form of minimum inhibitory concentrations (MICs) or susceptible, intermediate and resistant (SIR) calls \[[@bbx083-B16]\]. These panel data provide critical context for AMR research by allowing researchers to quickly build data sets for performing protein and gene comparisons, novel gene discovery, whole-genome variation analyses and machine learning (ML) experiments (described below).

To increase the number of genomes with AMR metadata in PATRIC and expand our ability to support AMR-based comparative analyses, we began searching the literature for studies that included sequenced bacterial genomes and AMR panel data. Oftentimes, panel data from these studies were not recorded in the public archives, so PATRIC becomes the only place, where both the assembled genomes and metadata are available in the same place. If a genome was assembled and deposited in GenBank \[[@bbx083-B7]\], we attach the AMR metadata directly to the corresponding genome in PATRIC. If the reads for a genome were deposited in the Sequence Read Archive (SRA) or the European Nucleotide Archive (ENA) \[[@bbx083-B17], [@bbx083-B18]\], we assemble and annotate the genome using PATRIC services \[[@bbx083-B1], [@bbx083-B4], [@bbx083-B19]\]. We then incorporate the genome into the database along with the metadata ([Supplementary Document S1](#sup1){ref-type="supplementary-material"}).

As laboratory methods for determining MIC values vary, incorporating these data into PATRIC requires a significant manual curation effort. When information is available from the study, we record how the MIC data were generated, including the laboratory method, the units of the measurement and the platform that was used to make the measurements. When an assertion about a phenotype is provided in the form of a SIR call, we record the laboratory standard from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@bbx083-B20]\] or the Clinical and Laboratory Standards Institute \[[@bbx083-B21]\] and the year of the standard. To date, we have attached metadata to PATRIC genomes for ∼9165 genomes and have assembled and annotated ∼6122 genomes from SRA and ENA ([Supplementary Table S1](#sup2){ref-type="supplementary-material"}). To date, all AMR metadata in PATRIC are phenotypes that are derived from laboratory analyses. Studies often assert the susceptibility or resistance of an organism based on the presence or absence of key AMR genes. We do not currently incorporate data that are only based on genotypic data. The complete collection of AMR data in PATRIC can be downloaded from the PATRIC FTP site: [ftp.patricbrc.org/patric2/current_release/RELEASE_NOTES/PATRIC_genomes_AMR.txt](http://ftp.patricbrc.org/patric2/current_release/RELEASE_NOTES/PATRIC_genomes_AMR.txt).

ML classifiers
--------------

As the PATRIC database was rapidly accumulating AMR panel data associated with sequenced genomes, a small number of studies were being published that explored using ML algorithms to study AMR \[[@bbx083-B22]\]. With a sufficient number of genomes and AMR panel data, ML algorithms can be used to predict AMR phenotypes and the genomic regions associated with AMR with no a priori knowledge of the underlying mechanisms. This is an appealing area of exploration for PATRIC because it allows us to leverage our growing metadata collection to predict AMR phenotypes within the annotation service and to identify AMR-associated genomic regions with single-nucleotide polymorphism (SNP)-level resolution, a feature that can be used to inform our ongoing manual protein annotation efforts.

In early 2016, we published a study describing the collection of AMR metadata for genomes and an ML approach that used the AdaBoost algorithm \[[@bbx083-B25], [@bbx083-B26]\] to build classifiers for predicting AMR \[[@bbx083-B16]\]. At the time, we had sufficient data to make predictions in the species *Acinetobacter baumannii*, *Mycobacterium tuberculosis*, *Staphylococcus aureus* and *Streptococcus pneumoniae* for nine antibiotics \[[@bbx083-B16]\] ([Table 1](#bbx083-T1){ref-type="table"}). Shortly thereafter, we collaborated with scientists at the Houston Methodist Research Hospital to build classifiers for *Klebsiella pneumoniae* covering 13 antibiotics using 1777 genomes collected in their hospital system between 2011 and 2015 \[[@bbx083-B27]\]. Using the same protocol as described in the Davis *et al.* \[[@bbx083-B16]\] and Long *et al.* studies \[[@bbx083-B27]\], we added 18 additional classifiers to the annotation system that have not been previously reported, including classifiers for *M. tuberculosis*, *Peptoclostridium difficile*, *Pseudomonas aeruginosa*, *S. aureus* and *S. pneumoniae* ([Table 1](#bbx083-T1){ref-type="table"}). Receiver operating characteristic (ROC) curves for the newly added classifiers are shown in [Figure 2](#bbx083-F2){ref-type="fig"}.

###### 

AMR classifiers in the PATRIC annotation system

  Species                        Antibiotic[^a^](#tblfn1){ref-type="table-fn"}   Resistant genomes[^b^](#tblfn2){ref-type="table-fn"}   Susceptible genomes[^b^](#tblfn2){ref-type="table-fn"}   F1 score   Initially described in
  ------------------------------ ----------------------------------------------- ------------------------------------------------------ -------------------------------------------------------- ---------- ------------------------
  *Acinetobacter baumannii*      Carbapenem                                      122                                                    110                                                      0.95       \[[@bbx083-B16]\]
  *Klebsiella pneumoniae*        Amikacin                                        1190                                                   364                                                      0.92       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Aztreonam                                       1377                                                   100                                                      0.75       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Cefoxitin                                       555                                                    976                                                      0.80       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Ciprofloxacin                                   119                                                    1435                                                     0.91       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Ertapenem                                       265                                                    178                                                      0.96       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Gentamicin                                      786                                                    768                                                      0.86       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Imipenem                                        1100                                                   453                                                      0.94       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Levofloxacin                                    246                                                    1307                                                     0.93       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Meropenem                                       1123                                                   430                                                      0.92       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Piperacillin--tazobactam                        322                                                    1230                                                     0.76       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Tetracycline                                    658                                                    896                                                      0.79       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Tobramycin                                      501                                                    1053                                                     0.94       \[[@bbx083-B27]\]
  *Klebsiella pneumoniae*        Co-trimoxazole                                  331                                                    1223                                                     0.87       \[[@bbx083-B27]\]
  *Mycobacterium tuberculosis*   Amikacin                                        210                                                    350                                                      0.91       This study
  *Mycobacterium tuberculosis*   Capreomycin                                     204                                                    350                                                      0.83       This study
  *Mycobacterium tuberculosis*   Isoniazid                                       250                                                    250                                                      0.88       \[[@bbx083-B16]\]
  *Mycobacterium tuberculosis*   Kanamycin                                       188                                                    250                                                      0.87       \[[@bbx083-B16]\]
  *Mycobacterium tuberculosis*   Ofloxacin                                       239                                                    250                                                      0.79       \[[@bbx083-B16]\]
  *Mycobacterium tuberculosis*   Rifampicin                                      250                                                    250                                                      0.86       \[[@bbx083-B16]\]
  *Mycobacterium tuberculosis*   Streptomycin                                    250                                                    250                                                      0.71       \[[@bbx083-B16]\]
  *Peptoclostridium difficile*   Azithromycin                                    213                                                    246                                                      0.97       This study
  *Peptoclostridium difficile*   Ceftriaxone                                     228                                                    86                                                       0.86       This study
  *Peptoclostridium difficile*   Clarithromycin                                  213                                                    246                                                      0.99       This study
  *Peptoclostridium difficile*   Clindamycin                                     310                                                    89                                                       0.74       This study
  *Peptoclostridium difficile*   Moxifloxacin                                    188                                                    271                                                      0.97       This study
  *Pseudomonas aeruginosa*       Levofloxacin                                    192                                                    290                                                      0.85       This study
  *Staphylococcus aureus*        Ciprofloxacin                                   467                                                    762                                                      0.98       This study
  *Staphylococcus aureus*        Clindamycin                                     350                                                    274                                                      0.97       This study
  *Staphylococcus aureus*        Erythromycin                                    484                                                    821                                                      0.96       This study
  *Staphylococcus aureus*        Gentamicin                                      162                                                    1144                                                     0.98       This study
  *Staphylococcus aureus*        Methicillin                                     707                                                    886                                                      0.99       \[[@bbx083-B16]\]
  *Staphylococcus aureus*        Penicillin                                      886                                                    156                                                      0.96       This study
  *Staphylococcus aureus*        Tetracycline                                    203                                                    1029                                                     0.97       This study
  *Staphylococcus aureus*        Co-trimoxazole                                  142                                                    178                                                      0.96       This study
  *Streptococcus pneumoniae*     Beta-lactam                                     2124                                                   584                                                      0.90       \[[@bbx083-B16]\]
  *Streptococcus pneumoniae*     Chloramphenicol                                 165                                                    289                                                      0.94       This study
  *Streptococcus pneumoniae*     Co-trimoxazole                                  2124                                                   584                                                      0.88       \[[@bbx083-B16]\]
  *Streptococcus pneumoniae*     Erythromycin                                    381                                                    324                                                      0.96       This study
  *Streptococcus pneumoniae*     Tetracycline                                    368                                                    290                                                      0.96       This study

^a^AMR data in PATRIC may be described as individual antibiotics or classes of antibiotics.

^b^Used for building the classifiers.

![ROC curves for AdaBoost-based AMR classifiers installed in the annotation service since the publication of the Davis *et al.* \[[@bbx083-B16]\] and Long *et al.* papers \[[@bbx083-B27]\]. Accuracy and F1 scores are displayed in each inset. ROC curves depict classifiers for (**A**) *P. difficile*, (**B**) *S. aureus* and (**C**) *K. pneumoniae* (Kpn), *M. tuberculosis* (Mtb), *P. aeruginosa* (Pae) and *S. pneumoniae* (Spn). Antibiotic abbreviations are: AZM, azithromycin; CC, clindamycin; CIP, ciprofloxacin; CLR, clarithromycin; CRO, ceftriaxone; E, erythromycin; GM, gentamicin; MFX, moxifloxacin; OX, ofloxacin; P, penicillin; SXT, trimethoprim sulfamethoxazole; TE, tetracycline.](bbx083f2){#bbx083-F2}

To date, we have maintained a policy of adding classifiers to the annotation system when their accuracies and F1 scores exceed 70% and their top feature *k*-mers relate to known AMR genes. The classifiers built in this project and described in [Table 1](#bbx083-T1){ref-type="table"} and [Figure 2](#bbx083-F2){ref-type="fig"} are integrated into the annotation service and can be accessed through PATRIC and RAST. Phenotype predictions and the associated genomic regions are available for browsing on both Web sites and are described in tutorials at <http://tutorial.theseed.org/>.

Our AMR metadata collection and classifier building efforts are ongoing at PATRIC. In many cases, the AMR metadata available in published studies report pan-resistant strains, which can be difficult to classify. In an effort to improve the accuracy of the classifiers, we are actively seeking strains with AMR metadata that improve the biological diversity of the collection. This includes collecting strains susceptible to many antibiotics. We are also comparing the results from several ML methods and are in the process of adding classifiers based on these other methods when they outperform AdaBoost \[[@bbx083-B25]\]. In this manner, an antibiotic and species would be paired with the best ML algorithm in the annotation system.

AMR---integrating data at the gene level
========================================

Data collection
---------------

Starting in 2015, the PATRIC annotation team, which also maintains the SEED \[[@bbx083-B28]\] and RAST projects \[[@bbx083-B3]\], began a focused effort to incorporate and manually curate protein functions relating to AMR. There are several well-known consortia that strive to provide standardized nomenclature for specific groups of antibiotic resistance genes including tetracycline resistance determinants \[[@bbx083-B29], [@bbx083-B30]\], and different classes of β-lactamases maintained by the Lahey Clinic \[[@bbx083-B31]\], the University of Stuttgart \[[@bbx083-B32], [@bbx083-B33]\] and the Institute Pasteur \[[@bbx083-B34]\]. There are also several well-respected databases that provide collections of AMR genes covering broad categories of AMR mechanisms including the Comprehensive Antibiotic Resistance Database (CARD) \[[@bbx083-B35]\], the Bacterial Antimicrobial Resistance Reference Gene Database \[[@bbx083-B36]\] hosted by the National Center for Biotechnology Information as part of the National Database of Antibiotic Resistant Organisms (NDARO) and ResFinder \[[@bbx083-B37]\]. These resources maintain reference sequences for each AMR gene type, providing each with well-curated informative product names (in the case of NDARO) or a specialized Antibiotic Resistance Ontology (ARO, provided by CARD). These collections enable accurate detection and annotation of specific AMR determinates in pathogen isolates by means of supporting the BLAST-based \[[@bbx083-B38], [@bbx083-B39]\] or hidden Markov model (HMM)-based \[[@bbx083-B40]\] screening of user-submitted sequences against representative sets of AMR sequences. However, in many cases, these AMR annotations project ambiguously because newly discovered proteins can match representative proteins with differing annotations at nearly equal BLAST similarities. For example, a novel CTX-M, SHV or TEM β-lactamase could potentially present the researcher with over a hundred nearly equal BLAST hits against highly homologous but clinically different reference sequence variants, making the choice of the most appropriate product name difficult. In many cases, the best choice would be a novel allele designation, rather than one of the existing curated product names. We believed that a manual curation effort was necessary to integrate AMR sequence variants into distinct functional roles (isofunctional protein families, which are integral for the SEED/PATRIC environment) to ensure that they can be unambiguously projected to the genomes in PATRIC by the annotation service.

As many resources focus more heavily on the horizontally transferred AMR genes, we began our curation effort by building functional roles for AMR-related porin and efflux pump proteins described in the literature that are often chromosomally encoded, reasoning that this would rapidly add new value to the scientific community. Afterward, this naturally led into an effort to incorporate annotations for proteins involved in tetracycline resistance. The proteins involved in efflux pumps are known to play an important role in this type of resistance \[[@bbx083-B41]\], and there are well-described annotation rules, which have been curated by the community for decades for naming them \[[@bbx083-B30], [@bbx083-B42]\]. More recently, we have been annotating class by class using publicly available resources when possible.

Curation process and *k*-mer projection
---------------------------------------

Significant manual curation and modification of the existing RAST/RASTtk automatic annotation pipeline were required to accommodate AMR-related functional roles, as their biology differs significantly from 'classic' functional roles encoding prokaryotic enzymatic and nonenzymatic housekeeping functions. The process of creating projectable AMR annotations starts with the incorporation of reference proteins from the literature and public resources. BLAST searches are used to compare reference sequences against the SEED database and PATRIC \[[@bbx083-B1]\]. The subsequent matching proteins are used to build alignments and trees, which are manually inspected to understand how specific or general an annotation is, and if it will project cleanly in the annotation system. When reference proteins from the literature create ambiguous BLAST matches or split high-similarity clades in the tree, the nomenclature is retained, but then combined into a single annotation that covers the entire clade. The training sets of representative AMR sequence variants from outside sources and the SEED database \[[@bbx083-B28]\] are then built. They form the basis for each AMR-related functional role. An annotation string for each of the functional roles is assigned, taking into account the SEED database internal nomenclature conventions as well as those developed by the AMR research community and accepted by CARD, ResFinder, NCBI and other resources. Signature *k*-mers (amino acid 8-mers) are built from these functional roles as described previously \[[@bbx083-B4]\], and the annotations are then projected to all of the genomes in PATRIC. Trees for the newly annotated AMR proteins are then manually inspected to identify clades that contain multiple annotations, indicating a lack of consistency. Inconsistencies are also identified by comparing the generation of protein families before and after the addition of a new function. The inconsistent proteins are manually re-annotated and this process is iterated until the annotations project stably and accurately across the entire database.

The PATRIC manual curation effort offers a variety of additional benefits to the field of AMR research. For example, this effort is helping to alleviate the well-documented problem of miss-annotation and over prediction of AMR annotations \[[@bbx083-B43], [@bbx083-B44]\]. We are doing this by systematically removing erroneous annotations, which implicate non-AMR-related proteins with antibiotic resistance functions, and by annotating and attaching literature references to these closely related proteins to prevent over-projection of AMR roles, and then curating their projection over the PATRIC collection as described above.

We occasionally discover clades of potential AMR proteins that are surrounded by solid AMR reference sequences, yet have not been described in any reference database. In these cases, we describe the protein as a 'putative' AMR protein of a given resistance type, if the sequence identity levels are 50% or better over the entire length of the protein, which enables functional projection. These are obvious targets for characterization in the laboratory. However, if a newly discovered hypothetical clade has a sequence identity that is \<50%, we use the less specific annotation string for all its members. In these cases, we use the following annotations: 'weak similarity to aminoglycoside N(6\')-acetyltransferase' and 'weak similarity to aminoglycoside N(3)-acetyltransferase'. These are obvious targets for characterization in the laboratory. Finally, having clean sets of AMR-related functional roles facilitates SNP and other comparative analyses at PATRIC and elsewhere by providing relevant sequence peer groups for variation research.

As of May 2017, the annotation of AMR determinants conferring resistance to tetracycline, β-lactam, aminoglycoside \[[@bbx083-B45], [@bbx083-B46]\], chloramphenicol \[[@bbx083-B47]\] and MLSKO (macrolides, lincosamides, streptogramins, ketolides and oxazolidinones) \[[@bbx083-B42], [@bbx083-B48], [@bbx083-B49]\] antibiotic classes has been completed. These include 450 functional roles for these five major antibiotic classes, as well as 36 roles for closely related non-AMR proteins. This collection comprises a combined set of 7370 reference and SEED proteins with AMR roles and 36 424 proteins with related non-AMR roles. The collection projects consistently to 1 610 744 AMR proteins with AMR roles and 2 518 252 proteins with related non-AMR roles in PATRIC. We have also associated literature references with the majority of the newly curated AMR functional roles in PATRIC, totaling 411 references. The curation effort is ongoing and is focusing on proteins conveying resistance to quinolone, vancomycin, fosfomycin, rifampin/rifamycin, nitroimidazole, bleomycin and other antibiotic classes.

Visualization of AMR data at PATRIC
===================================

Several new interfaces have been developed on the PATRIC Web site to allow researchers to fully explore the AMR data available in the resource. These interfaces include information that is summarized across all genomes for the available antibiotics, at the taxon level, and for individual genomes and genes. Details on each of these interfaces are described below.

Antibiotic view
---------------

Data from PubChem \[[@bbx083-B50]\] are now integrated for nearly 100 specific antibiotics that can be viewed on landing pages designed especially to display this information. Each individual antibiotic has a landing page with several tabs that provide a general overview, specific information on the AMR phenotype, the genes associated with that phenotype and the regions within the individual genes or genomes that are linked to resistance or susceptibility to that specific drug ([Figure 3](#bbx083-F3){ref-type="fig"}).

![Summary information for the antibiotic methicillin at PATRIC. The antibiotic interface provides a summary of the antibiotic, its synonyms and actions, and also provides links via separate tabs for AMR phenotypes, genes and regions across all the data available in PATRIC.](bbx083f3){#bbx083-F3}

The overview tab includes a general description of the drug, the chemical structure, the mechanism of action, a description of the pharmacological activity and class and known synonyms. The AMR phenotype tab provides a list of all the genomes that have been identified as being susceptible or resistant to that antimicrobial. This tab also includes the laboratory typing method and platform, and the testing standard if that information is available. A third tab, called AMR genes, displays information on the genes associated with resistance. The final tab, AMR regions, includes the location of the specific *k*-mers that are associated with the genome's phenotype.

Taxon-level view
----------------

PATRIC organizes relevant data for all the available sequenced bacterial and archaeal genomes according to NCBI taxonomy \[[@bbx083-B51]\]. Data are summarized at each level, from the highest (the Superkingdoms: Bacteria and Archaea) to the strain (or isolate) from which the genome has been sequenced. For each taxonomic level with associated AMR data, PATRIC provides several summaries. A bar graph summarizing the antibiotics, the AMR phenotype (resistant, intermediate or susceptible) and the number of genomes that match that phenotype is available on the overview tab at the top of the main landing page for each taxon ([Figure 4A](#bbx083-F4){ref-type="fig"}). Clicking on any of the antibiotics displayed in the graph will open a new page that summarizes all the genomes from that taxon level that have the particular AMR phenotype. An alternate tabular view of the data is also available ([Figure 4B](#bbx083-F4){ref-type="fig"}). The taxon-level summary page also includes an AMR phenotype tab that lists all of the genomes within the selected taxon that have an AMR phenotype, and the data that are associated with it, including specific treatments, phenotypes or laboratory methods. All tables in PATRIC include a dynamic filter for rapid filtering of the genomes based on metadata selections.

![A taxon-level summary on the PATRIC Web site describing AMR phenotype data across all of the genomes that are part of the *Staphylococcus* genus. (**A**) A bar graph summarizes the antibiotics, the AMR phenotype (resistant, intermediate or susceptible) and the number of genomes that match that phenotype. (**B**) The AMR phenotype tabular view, which shows all the genomes that have associated AMR data, includes a dynamic filter for rapid selection of genomes based on the metadata.](bbx083f4){#bbx083-F4}

Gene view and predicted regions associated with AMR phenotypes
--------------------------------------------------------------

PATRIC provides a summary of data at the gene level, where the physical characteristics of a gene, its functional role(s), available experimental data and associated publications are provided. This view also includes information on homology to genes known to be important in AMR. In addition, PATRIC provides a view for predicted regions within some genes that are associated with AMR phenotypes. The *k*-mer regions predicted by the ML classifiers are visually indicated and their genomic region can be seen on the genome browser ([Figure 5](#bbx083-F5){ref-type="fig"}).

![AMR predicted regions, located in the genome of *S. aureus* strain 08S00974, as visualized in the PATRIC JBrowse viewer \[[@bbx083-B57]\]. These predicted regions, numbered sequentially by their occurrence in the genome as 'classifier_predicted_regions 12--15', were predicted by the ML algorithm that is being used to predict AMR phenotypes. The predicted regions are located in and around a gene (fig\|1280.11691.peg.56) that is annotated as 'Tetracycline resistance, MFS efflux pump  = \> Tet(K)'. The annotation for this gene came from the focused manual curation effort at PATRIC to incorporate and propagate information for specific genes that were known to play an important role in AMR.](bbx083f5){#bbx083-F5}

Future improvements
===================

We continue to peruse resources and publications to identify new genomes and AMR genes to incorporate into PATRIC. These will be used to expand the AMR phenotype predictions and AMR gene analysis to new genera and new antibiotics. We plan to map AMR properties to the genus-specific families (PLfams) to support comparative analysis of AMR genes, incorporate new AMR gene trees and allow users to build nucleotide-based multiple sequence alignments to identify SNPs and their association with AMR phenotypes. We are acutely aware that several important types of AMR determinants are not amenable to being encoded and automatically propagated via the automated annotation propagation strategy described above. These include antibiotic targets, which are largely cellular proteins performing essential household cellular functions, and such proteins are grouped into 'classic' functional roles in SEED/PATRIC. They carry functional annotations that are unrelated to AMR. Antibiotic susceptibility in these target proteins is determined by a few, or even a single, non-synonymous mutation in the corresponding gene \[[@bbx083-B52]\]. Likewise, single mutations in noncoding DNA regions, including promoters, operators and attenuators, can lead to dramatic increase in MIC, or an increase in resistance levels to particular antimicrobials \[[@bbx083-B55], [@bbx083-B56]\]. These cases will be treated separately in PATRIC. We are in the process of designing tools specific for SNP detection and analysis targeted at the gene level. While PATRIC does not currently enable examining AMR data from metagenomes or from population-based studies, this is something that we plan to provide in future releases.

Key PointsPATRIC includes AMR information at both the genome and gene level, and uses manual curation and ML to integrate these data into the annotation service. A large collection of AMR-specific functional roles has been manually curated, and this information is propagated by the annotation service. With summaries of the available data across all taxonomic levels and new interfaces, researchers can quickly locate and examine these data in their private genomes and compare with the PATRIC collection.

Supplementary Material
======================
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Click here for additional data file.
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Click here for additional data file.
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